Oramed Pharmaceuticals Other Cashflows From Financing Activities Over Time
| ORMP Stock | USD 2.49 0.03 1.22% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Oramed Pharmaceuticals Performance and Oramed Pharmaceuticals Correlation. Oramed |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oramed Pharmaceuticals. If investors know Oramed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oramed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.51 | Quarterly Revenue Growth (1.00) | Return On Assets (0.04) | Return On Equity 0.0289 |
The market value of Oramed Pharmaceuticals is measured differently than its book value, which is the value of Oramed that is recorded on the company's balance sheet. Investors also form their own opinion of Oramed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oramed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oramed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oramed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oramed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oramed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oramed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Cashflows From Financing Activities Analysis
Compare Oramed Pharmaceuticals and related stocks such as Protalix Biotherapeutics, Corvus Pharmaceuticals, and Aldeyra Other Cashflows From Financing Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | (6.3 M) | 277 K | 1.2 M | 66.9 M | 46 K | 534 K | 19.7 M | 9.5 M | (4.8 M) | (883 K) | 472 K | 46.2 M | 2 K | 712 K | 676.4 K |
| CRVS | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 13.8 M | 94.9 M | 71.4 M | 731 K | 393 K | 24.0 | 88 K | 1.2 M | (23.3 M) | 12 K | 11.4 K |
| ALDX | 1.8 M | 1.8 M | 1.8 M | 3.8 M | 1.4 M | (36.2 K) | (225.2 K) | (165.9 K) | (1.4 M) | 30 M | 1.2 M | 4.7 M | 1.2 M | (227.7 K) | (216.3 K) |
| CKPT | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 570 K | (400 K) | 28.6 M | (2.1 M) | (2 M) | (1 M) | (2.7 M) | 6.8 M | 7.2 M |
| BLRX | 294.8 K | 263 | 535 | 2.9 K | (18.2 M) | 467 K | 9.3 M | (15.9 M) | 9.7 M | 1000 | 2 M | 10.9 M | 5 K | 3 M | 3.1 M |
| ARDX | 290 K | 290 K | 290 K | (1000) | 71 K | 689 K | 191.2 M | 685 K | 49.8 M | 574 K | 1.9 M | 1.3 M | 9.8 M | 4.7 M | 4.4 M |
| LXRX | 3.4 M | 3.6 M | 1.4 M | (26 K) | 84.1 M | 70 K | 2 M | 145.9 M | 12.5 M | (2.2 M) | 216.6 M | 11.7 M | (71.1 M) | (49.9 M) | (47.4 M) |
| MCRB | 9.4 M | 9.4 M | 9.4 M | 944 K | 124.4 M | 140.3 M | 2.1 M | 116 K | 404 K | 50 M | 14.9 M | 2.1 M | 2.7 M | 3 M | 2.9 M |
| IBRX | 230 K | 230 K | 230 K | 230 K | 64.5 M | (2.4 M) | (1.1 M) | (1 M) | (123 K) | 91.3 M | 673 K | 2.4 M | (881 K) | 189.6 M | 199.1 M |
| XFOR | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 18.5 M | 83.5 M | 136 K | 10.6 M | 283 K | 260 K | (4.6 M) | 8.1 M | 11.5 M |
| MREO | (868 K) | (868 K) | (868 K) | (868 K) | (868 K) | (868 K) | 467.7 K | 18.7 M | (2 M) | (2.5 M) | (23.4 M) | (253.7 K) | 350 K | (444 K) | (466.2 K) |
| INZY | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M | 23 K | 33.8 M | 609 K | 12.6 M | 322 K | 305.9 K |
| TERN | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 99.8 M | 94 K | 68.6 M | (2 M) | (158 K) | 1 M | 972.8 K |
| LPTX | 2.4 M | 2.4 M | 2.4 M | (114 K) | 198 K | 16 K | 25.6 M | (1.4 M) | 872 K | (437 K) | 25.8 M | 813 K | (210 K) | (29 K) | (27.6 K) |
| ZURA | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 505 K | 7.2 M | 14.9 M | 8.3 M |
| CYTO | 3.9 M | 3.9 M | 3.9 M | 13.8 M | (428.7 K) | 20.9 M | 11.4 M | (2.7 M) | (2.4 M) | (952.4 K) | 15.4 M | 6.7 M | 3.9 M | 9.6 M | 5.3 M |
| IMMX | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 468.3 K | (802) | (56.7 K) | (229.4 K) | (217.9 K) |
| ENVB | 700 K | 27.5 K | 8 K | 20.5 K | (2 K) | 6.2 M | 3.8 M | 2.1 B | (1.7 M) | 560 | 3.4 M | 3.3 M | 958 K | (1.3 M) | (1.3 M) |
| PALI | (125.2 K) | 1.7 M | 138.9 K | 7.6 M | 3.8 M | (847.1 K) | 313.5 K | 346.9 K | 207 K | 10.2 M | (87 K) | 19.6 M | 1.6 M | 2.2 M | 3.3 M |
| HEPA | 600 K | 600 K | 600 K | (15 K) | 335 K | (83.3 K) | (502.2 K) | 116.3 K | 11.6 M | 13.4 M | 198.6 K | (165.6 K) | (2 M) | 4.5 M | 2.6 M |
| OCEA | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 64 K | 96 K | (2.1 M) | 52.1 M | 54.7 M |
| ELEV | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 90 M | (11 K) | (451 K) | 1.5 M | 1.4 M |
Oramed Pharmaceuticals and related stocks such as Protalix Biotherapeutics, Corvus Pharmaceuticals, and Aldeyra Other Cashflows From Financing Activities description
My Equities
My Current Equities and Potential Positions
| Oramed Pharmaceuticals | ORMP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.49
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.